Applied Therapeutics IncNASDAQ:APLT
- LAST PRICE4.3800
- TODAY'S CHANGE (%)0.0300 (0.6897%)
- Bid / Lots4.2600/ 1
- Ask / Lots4.6000/ 4
- Open / Previous Close4.3500 / 4.3500
- Day Range
- 52 Week Range
- Volume556,330
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APLT |
|---|---|---|
| 09:32 ET | 11874 | 4.36 |
| 09:34 ET | 100 | 4.36 |
| 09:36 ET | 3139 | 4.335 |
| 09:38 ET | 11474 | 4.36 |
| 09:39 ET | 2157 | 4.345 |
| 09:41 ET | 494 | 4.3517 |
| 09:43 ET | 110095 | 4.35 |
| 09:45 ET | 3687 | 4.37 |
| 09:48 ET | 1648 | 4.3867 |
| 09:52 ET | 7656 | 4.39 |
| 09:56 ET | 403 | 4.4 |
| 09:57 ET | 3505 | 4.39 |
| 09:59 ET | 3202 | 4.39 |
| 10:01 ET | 1900 | 4.4297 |
| 10:03 ET | 2401 | 4.42 |
| 10:06 ET | 1426 | 4.43 |
| 10:08 ET | 4720 | 4.449 |
| 10:10 ET | 5065 | 4.42 |
| 10:12 ET | 1300 | 4.38 |
| 10:14 ET | 3003 | 4.4 |
| 10:15 ET | 1000 | 4.41 |
| 10:17 ET | 1200 | 4.41 |
| 10:19 ET | 1000 | 4.44 |
| 10:21 ET | 1100 | 4.44 |
| 10:24 ET | 1145 | 4.445 |
| 10:26 ET | 1100 | 4.445 |
| 10:28 ET | 1522 | 4.45 |
| 10:30 ET | 2669 | 4.445 |
| 10:32 ET | 1412 | 4.47 |
| 10:33 ET | 900 | 4.46 |
| 10:35 ET | 1200 | 4.46 |
| 10:37 ET | 2268 | 4.445 |
| 10:39 ET | 935 | 4.445 |
| 10:42 ET | 5178 | 4.455 |
| 10:44 ET | 2574 | 4.47 |
| 10:46 ET | 6804 | 4.44 |
| 10:48 ET | 1725 | 4.4414 |
| 10:50 ET | 1670 | 4.445 |
| 10:51 ET | 3310 | 4.455 |
| 10:53 ET | 1405 | 4.44 |
| 10:55 ET | 1200 | 4.44 |
| 10:57 ET | 6507 | 4.42 |
| 11:00 ET | 2302 | 4.39 |
| 11:02 ET | 1942 | 4.37 |
| 11:04 ET | 4443 | 4.35 |
| 11:06 ET | 600 | 4.35 |
| 11:08 ET | 1060 | 4.35 |
| 11:09 ET | 1384 | 4.35 |
| 11:11 ET | 2900 | 4.355 |
| 11:13 ET | 1436 | 4.36 |
| 11:15 ET | 1736 | 4.355 |
| 11:18 ET | 2154 | 4.36 |
| 11:20 ET | 1100 | 4.355 |
| 11:22 ET | 899 | 4.355 |
| 11:24 ET | 1000 | 4.35 |
| 11:26 ET | 1500 | 4.35 |
| 11:27 ET | 2751 | 4.36 |
| 11:29 ET | 1100 | 4.37 |
| 11:31 ET | 1940 | 4.355 |
| 11:33 ET | 2886 | 4.355 |
| 11:36 ET | 2639 | 4.35 |
| 11:38 ET | 300 | 4.34 |
| 11:40 ET | 3004 | 4.355 |
| 11:42 ET | 3131 | 4.345 |
| 11:44 ET | 4097 | 4.365 |
| 11:45 ET | 1165 | 4.34 |
| 11:47 ET | 300 | 4.35 |
| 11:49 ET | 1400 | 4.355 |
| 11:51 ET | 1903 | 4.35 |
| 11:54 ET | 4600 | 4.35 |
| 11:56 ET | 500 | 4.35 |
| 11:58 ET | 1765 | 4.35 |
| 12:00 ET | 2947 | 4.345 |
| 12:02 ET | 4587 | 4.32 |
| 12:03 ET | 300 | 4.32 |
| 12:05 ET | 2651 | 4.34 |
| 12:07 ET | 100 | 4.34 |
| 12:09 ET | 200 | 4.34 |
| 12:12 ET | 1256 | 4.3413 |
| 12:14 ET | 3747 | 4.36 |
| 12:16 ET | 1916 | 4.37 |
| 12:18 ET | 3827 | 4.36 |
| 12:20 ET | 1252 | 4.35 |
| 12:21 ET | 2496 | 4.35 |
| 12:23 ET | 1399 | 4.35 |
| 12:25 ET | 5653 | 4.345 |
| 12:27 ET | 3404 | 4.365 |
| 12:30 ET | 1400 | 4.365 |
| 12:32 ET | 3797 | 4.355 |
| 12:34 ET | 2149 | 4.35 |
| 12:36 ET | 3600 | 4.355 |
| 12:38 ET | 4000 | 4.355 |
| 12:39 ET | 2500 | 4.355 |
| 12:41 ET | 3105 | 4.345 |
| 12:43 ET | 2168 | 4.34 |
| 12:45 ET | 3379 | 4.33 |
| 12:48 ET | 4715 | 4.355 |
| 12:50 ET | 4896 | 4.34 |
| 12:52 ET | 10992 | 4.36 |
| 12:54 ET | 968 | 4.36 |
| 12:56 ET | 13465 | 4.365 |
| 12:57 ET | 13119 | 4.355 |
| 12:59 ET | 77347 | 4.38 |
Jul 1, 2024
Applied Therapeutics Added to Russell 3000(R) Index, from 7:00AM ET on Monday Jul 01, 2024 by Dow Jones
7:00AM ET on Monday Jul 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Applied Therapeutics Inc | 500.5M | -2.3x | --- |
Iteos Therapeutics Inc | 533.9M | -3.9x | --- |
Northwest Biotherapeutics Inc | 504.9M | -6.6x | --- |
Annexon Inc | 496.2M | -3.3x | --- |
Kalvista Pharmaceuticals Inc | 494.4M | -3.7x | --- |
Astria Therapeutics Inc | 494.2M | -3.9x | --- |
Company Information
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
Contact Information
- Headquarters
- 545 FIFTH AVENUE, SUITE 1400NEW YORK, NY, United States 10017
- Phone
- 212-220-9226
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Shoshana Shendelman
- Chief Financial Officer and Principal Financial Officer, Director
- Leslie Funtleyder
- Chief Operating Officer and Chief Business Officer
- Constantine Chinoporos
- Chief Accounting Officer
- Catherine Thorpe
- Chief Commercial Officer
- Dale Hooks
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $500.5M |
|---|---|
Revenue (TTM) | $-477.0K |
Shares Outstanding | 114.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.99 |
EPS | $-1.91 |
Book Value | $-0.20 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
